All Updates

All Updates

icon
Filter
Funding
Curis announces USD 15.1 million-registered direct offering
Precision Medicine
Jul 6, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 6, 2023

Curis announces USD 15.1 million-registered direct offering

Funding

  • Massachusetts-based Biotechnology company Curis has announced a registered direct offering of 18.4 million common shares. The company aims to raise approximately USD 15.1 million for USD 0.82 per share. The offering is expected to close on July 10, 2023.

  • The net proceeds are expected to be utilized in R&D, working capital, and general corporate purposes. 

  • Curis is a biotechnology company focused on the development of innovative cancer therapeutics. Its lead product, Erivedge, is approved for treating advanced basal cell carcinoma. Curis has multiple drug candidates in development, including Fimepinostat, CA-170, CA-4948, and CI-8993, targeting various cancer types. Through collaborations with Aurigene, ImmuNext, and Genentech, Curis is working on various treatments, including immune checkpoint antagonists and kinase inhibitors, which are currently undergoing clinical testing for hematologic malignancies and other cancer types.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.